

Cite this: *Chem. Sci.*, 2024, 15, 15291

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Comparative study of the antiproliferative activity of heterometallic carbene gold(I)–platinum(II) and gold(I)–palladium(II) complexes in cancer cell lines†

Martin C. Dietl,<sup>a</sup> Melina Maag,<sup>a</sup> Sophia Ber,<sup>a</sup> Frank Rominger,<sup>a</sup> Matthias Rudolph,<sup>a</sup> Isabella Caligiuri,<sup>b</sup> Pacome K. Andele,<sup>bc</sup> Ibraheem A. I. Mkhalid,<sup>d</sup> Flavio Rizzolio,<sup>be</sup> Pablo A. Nogara,<sup>f</sup> Laura Orian,<sup>g</sup> Thomas Scattolin,<sup>g</sup> and A. Stephen K. Hashmi<sup>ad</sup>

Received 10th July 2024  
Accepted 26th July 2024

DOI: 10.1039/d4sc04585h

rsc.li/chemical-science

The stepwise, one-pot synthesis of heterobimetallic carbene gold(I) platinum(II) complexes from readily available starting materials is presented. The protecting group free methodology is based on the graduated nucleophilicities of aliphatic and aromatic amines as linkers between both metal centers. This enables the selective, sequential installation of the metal fragments. In addition, the obtained complexes were tested as potential anticancer agents and directly compared to their gold(I) palladium(II) counterparts.

## Introduction

Encompassing both early, as well as late transition metals,<sup>1,2</sup> heterobimetallic complexes have emerged as an intriguing subclass of coordination, as well as organometallic compounds. In these structures, the metal centers can be connected either by a direct metal–metal bond<sup>3–6</sup> or *via* bridging ligands.<sup>7–9</sup> Depending on the ligands and the coordination sphere of the metals used, supramolecular,<sup>10,11</sup> oligo-<sup>12</sup> and polymeric<sup>13,14</sup> or monomolecular<sup>15–17</sup> structures are attainable, that find application in catalysis,<sup>18,19</sup> in materials chemistry,<sup>20,21</sup> as well as in medicinal chemistry.<sup>22–26</sup> Regarding acyclic diaminocarbenes however, only a limited number of studies about the synthesis and application of homo-<sup>27</sup> as well as heterometallic complexes<sup>28</sup> are found.

In our pursuit to synthesize metal carbene complexes,<sup>29–36</sup> inspired by the pioneering works of Chugaev<sup>37</sup> and Shaw,<sup>38</sup>

Bonati and Minghetti,<sup>39,40</sup> we have recently succeeded in obtaining heterobimetallic complexes,<sup>28</sup> containing the pharmacologically relevant metal centers gold(I)<sup>41</sup> and palladium(II).<sup>42</sup> In this study, we extended our synthetic methodology to introduce platinum(II) as another medically important metal center<sup>42,43</sup> into the heterobimetallic complex scaffold. Given that there are only a few comparative studies between palladium and platinum complexes bearing the same organometallic fragments,<sup>44,45</sup> we regard this concept as an ideal tool for a direct comparison of bimetallic systems by changing only one parameter, namely the central metal atom attached to the aryl amine subunit.

It should be stressed that the main advantage of heterobimetallic compounds in medicinal chemistry is their ability to harness the complementary properties of diverse metal centers. For instance, combining transition metal centers with redox-active properties alongside inert or biocompatible metal centers can introduce redox-switchable behaviour to the compounds.<sup>46–61</sup> This attribute proves valuable in crafting agents for targeted drug delivery, enabling controlled release of therapeutic payloads triggered by external stimuli like alterations in pH or the application of electromagnetic fields.<sup>62,63</sup> Moreover, the incorporation of different metal centers in heterobimetallic compounds with multifunctionality, allows the concurrent modulation of multiple biological pathways associated with a specific disease.<sup>46–55</sup> By leveraging the distinct reactivities of different metal centers, researchers can engineer compounds capable of exerting synergistic effects on intricate biological systems, thus enhancing therapeutic outcomes.<sup>46–61</sup>

Additionally, in the realm of drug resistance, heterobimetallic compounds present a promising approach to overcoming challenges associated with multidrug-resistant pathogens or cancer cells.<sup>46–65</sup> By capitalizing on the unique

<sup>a</sup>Organisch-Chemisches Institut, Heidelberg University, Im Neuenheimer Feld 270, 69120 Heidelberg, Germany. E-mail: hashmi@hashmi.de

<sup>b</sup>Pathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS via Franco Gallini 2, 33081, Aviano, Italy

<sup>d</sup>Dipartimento di Scienze Molecolari e Nanosistemi, Università Ca' Foscari, Campus Scientifico Via Torino 155, 30174 Venezia-Mestre, Italy

<sup>f</sup>Chemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

<sup>g</sup>Dipartimento di Scienze Molecolari e Nanosistemi, Università Ca' Foscari, Campus Scientifico Via Torino 155, 30174 Venezia-Mestre, Italy

<sup>h</sup>Instituto Federal de Educação, Ciência e Tecnologia Sul-rio-grandense (IFSul), Av. Leonel de Moura Brizola, 2501, 96418-400, Bagé, RS, Brazil

<sup>i</sup>Dipartimento di Scienze Chimiche, Università degli Studi di Padova, via Marzolo 1, 35131 Padova, Italy. E-mail: thomas.scattolin@unipd.it

† Electronic supplementary information (ESI) available: Experimental procedures, analytical data and spectra. CCDC 2339445. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4sc04585h>



mechanisms of action facilitated by the synergistic interactions between different metal ions, these compounds can evade resistance mechanisms that render conventional monometallic drugs ineffective.


Herein we were able to test and compare both series of heterobimetallic carbene gold(i) palladium(ii) and gold(i) platinum(ii) complexes against various cancer cell lines, as well as their cytotoxicity against non-cancerous cells (Scheme 1).

## Results and discussion


Our research group has previously demonstrated the synthesis of heterobimetallic gold(i) palladium(ii) complexes through the nucleophilic attack of aminobenzylamines on isonitrile metal complexes.<sup>28</sup> This methodology relies on the addition of primary or secondary amines to isonitrile metal complexes. Depending on the nature of the amine, this template-controlled reaction yields either cyclic or acyclic carbene metal complexes.<sup>29–36</sup>

Aminobenzylamines possess both aliphatic and aromatic amine functionalities. Due to the higher nucleophilicity of aliphatic amines compared to aromatic amines, the reaction between aminobenzylamine and isonitrile gold(i) complexes selectively yields amino functionalized carbene gold(i) complexes. The yet unreacted free amino group originating from the aromatic core of the aminobenzylamine can then serve as a nucleophile for a subsequent addition to another isonitrile metal complex, resulting in the formation of heterobimetallic carbene complexes. Consequently, we synthesized a series of isonitrile platinum(ii) complexes from the precursor complex [PtCl<sub>2</sub>(COD)], which is readily available from the commercially available K<sub>2</sub>PtCl<sub>4</sub> and cyclooctadiene.<sup>66</sup> [PtCl<sub>2</sub>(COD)] was reacted with 2.20 equiv. of isonitrile in chloroform at reflux to furnish the corresponding isonitrile platinum(ii) complexes **1a–c** in excellent yields (Scheme 2a). Purification was simply achieved by crystallization of the desired products by addition of *n*-pentane to the reaction mixture. The amino functionalized carbene gold(i) complexes **2a–g**, encompassing aliphatic and aromatic substituents, as well as the free amino group at different positions on the phenyl ring were synthesized according to our previous report (Scheme 2b).<sup>28</sup>

### a) Synthesis of isonitrile platinum(ii) complexes




### b) Previously reported amino carbene gold(i) complexes



Scheme 2 (a) Synthesis of isonitrile platinum(ii) complexes from [PtCl<sub>2</sub>(COD)]. Conditions: 2 (668 μmol, 1.00 eq.), isonitrile (1.47 mmol, 2.20 eq.), CHCl<sub>3</sub>, 70 °C, 1 h; (b) previously reported amino carbene gold(i) complexes.<sup>28</sup>


These complexes were subsequently used as nucleophiles for the generation of heterobimetallic carbene gold(i) platinum(ii) complexes.

Hence, one equivalent of an amino carbene gold(i) complex **2a–g** was brought to reaction with one equivalent of an isonitrile platinum(ii) complex **1a–c**. Firstly, the solvent of choice was dichloromethane, since in our previous report the reaction between amino carbene gold(i) complexes and isonitrile palladium(ii) complexes performed well.<sup>28</sup> Notably, in the case of platinum(ii) isonitriles, performing the reaction under these conditions did not lead to the formation of any product and both starting materials were fully recovered. In another report from our group, we discovered that the addition of aromatic amines to isonitrile metal complexes proceeded faster, if tetrahydrofuran was used as solvent.<sup>35</sup> In line with these findings, the reaction between amino functionalized carbene gold(i) complexes **2b–g** and the isonitrile platinum(ii) complexes **1b–c** in tetrahydrofuran at room temperature showed full conversion of the starting material after a reaction time of 24 hours. Purification of the heterobimetallic carbene gold(i) platinum(ii) complexes **3a–l** was simply achieved by addition of *n*-pentane to the reaction mixture, which led to the precipitation of the desired product. The reaction protocol generally worked for most combinations of amino functionalized carbene gold(i) complexes and isonitrile platinum(ii) complexes in moderate to good yields (Scheme 3a). In general, there was no great influence of the substitution pattern at the amino functionalized carbene gold(i) complexes on the yield of the reaction. Also, no great differences in yield were observed if the free amino group was found at the 3- or 4-position of the aromatic ring of the amino functionalized carbene gold(i) complex. However, if complex **2a** was used, in which the free amino group was located at the 2-position, no reaction was observed. This is most likely attributed to the 2-position of the free amino group, furnishing a sterically too demanding reaction site. Furthermore, no reaction occurred if the aliphatic isonitrile platinum(ii) complex **1a** was used. These unsuccessful reactions indicate a general limitation of the reaction to aromatic isonitrile platinum(ii)



Scheme 1 Expansion of the synthetic protocol of heterobimetallic gold(i) palladium(ii) complexes<sup>28</sup> towards heterobimetallic gold(i) platinum(ii) complexes and testing their *in vitro* anticancer activity in a comparative study.





**Scheme 3** (a) Multistep synthesis of heterobimetallic carbene gold(I) platinum(II) complexes. *Conditions:* **2b–g** (92–114  $\mu\text{mol}$ , 1.00 eq.), **1b–c** (92–114  $\mu\text{mol}$ , 1.00 eq.), THF, r.t., 12 h. (b) One pot synthesis of heterobimetallic carbene gold(I) platinum(II) complexes. *Conditions:*  $[\text{AuCl}(\text{DMS})]$  (102  $\mu\text{mol}$ , 1.00 eq.), isonitrile (102  $\mu\text{mol}$ , 1.00 eq.), 3-, or 4-aminobenzylamine (102  $\mu\text{mol}$ , 1.00 eq.), **1b–c** (102  $\mu\text{mol}$ , 1.00 eq.), THF, r.t. 24 h; DIPP = 2,6-diisopropylphenyl-, Mes = mesityl-.

complexes and sterically less demanding amino carbene gold(I) complexes. Increasing the reaction temperature overall led to the decomposition of the amino functionalized carbene gold(I) complex. It was therefore not possible to run the reaction at elevated temperatures to form any product. All reaction products were characterized spectroscopically to verify the formation of the desired heterobimetallic carbene gold(I) platinum(II) complexes. In the IR spectra of the isonitrile platinum(II) complexes **1b–c**, the isonitrile stretching mode at  $\tilde{\nu} = 2195$  to  $2193 \text{ cm}^{-1}$  vanished, while a new isonitrile stretching mode in the complexes **3a–l** at a slightly lower wavenumber at  $\tilde{\nu} = 2185$  to  $2192 \text{ cm}^{-1}$  appeared. This indicates, that one of the isonitrile ligands was converted to a carbene ligand, while the other coordinated isonitrile ligand remained intact. Furthermore, in the  $^{13}\text{C}$  NMR spectrum the formation of the new carbene unit coordinated to the platinum(II) metal center was observed as a resonance in the  $^{13}\text{C}$  NMR spectrum at  $\delta = 170$  to  $159 \text{ ppm}$ . By  $^{195}\text{Pt}$  NMR spectroscopy the change of the chemical surroundings of the platinum(II) center could be studied. While the isonitrile platinum(II) complexes showed a resonance of the  $^{195}\text{Pt}$  nucleus at  $\delta = -3754$  to  $-3750 \text{ ppm}$ , after the reaction it shifted to  $\delta = -3496$  to  $-3551 \text{ ppm}$ .

Additionally, the experimental data from high-resolution mass spectra of the  $[\text{M–Cl}]$  fragments and their isotopic patterns match their calculated values. Furthermore, the bulk purity was confirmed by elemental analysis.

The rotation of substituents around the  $\text{N–C}_{\text{carbene}}$  bond of the acyclic carbene units leads to four different possible conformers per metal center, the so called rotamers. Since there are two metal centers present in the complexes **3a–l**, theoretically 16 different rotamers are possible. However, not all 16 possible rotamers were observed. For all complexes with 4-aminobenzylamine as the linker between both metal centers **3g–l**, no rotational isomerism was observed at all, since in the  $^1\text{H}$ ,  $^{13}\text{C}$ , as well as  $^{195}\text{Pt}$  NMR spectra only one species was present. If, on the other hand, 3-aminobenzylamine was employed as the linker between the gold(I) and platinum(II) metal centers, in some cases two rotamers were observed. This is especially evident in the  $^{195}\text{Pt}$  NMR spectra, because for the complexes **3b–f**, two distinct resonances in the range of  $\delta = -3488$  to  $-3501 \text{ ppm}$  and  $\delta = -3523$  to  $-3530 \text{ ppm}$  appear, indicating the presence of two species. After expanding the multistep synthesis of heterobimetallic complexes to gold(I) and platinum(II) as metal centers, we were curious, if also a one-pot protocol was applicable. The direct access to heterobimetallic complexes would not only save time but would also abbreviate the multiple purification steps, leading to a more efficient and environmentally friendly protocol. Hence, the reactions were carried out with the commercially available  $[\text{AuCl}(\text{DMS})]$  which was firstly reacted in tetrahydrofuran at room temperature with one equivalent of isonitrile and one equivalent of either 3-, or 4-aminobenzylamine to form the corresponding amino functionalized carbene gold(I) complex *in situ*. Finally the addition of one equivalent of a isonitrile platinum(II) complex **1b–c** led to the formation of the desired heterobimetallic carbene gold(I) platinum(II) complexes **3a–k** in moderate to good yields (Scheme 3b). Overall, the yields stemming from the one-pot protocol did not deviate significantly from the yields from the multistep approach. Therefore, a one-pot protocol offers an elegant and direct path to heterobimetallic carbene gold(I) platinum(II) complexes.

Slow diffusion of *n*-pentane in saturated solutions of **3c** in 1,2-dichloroethane furnished single crystals suitable for single crystal X-ray diffraction. The obtained molecular structure in the solid state reveals the proper connectivity of all atoms (Fig. 1). The gold(I) center shows the typical linear coordination sphere, while the platinum(II) metal center exhibits a square planar molecular geometry. Furthermore, no metallophilic interactions were observed.

Despite the plethora of platinum(II)- and palladium(II) based metal drugs against cancer, there is still a scarcity of comparative studies, in which the metal complexes only differ in the metal center while the organometallic fragment remains the same. Our established reaction protocol allows the introduction of platinum(II), as well as palladium(II) into the gold(I) containing heterobimetallic scaffold. This offers the possibility for the synthesis of similar complexes, only differing in one metal center. For that, we aimed to compare the activity of the synthesized heterobimetallic carbene gold(I) platinum(II)






Fig. 1 Molecular structure of **3c** (CCDC 2339445) in the solid state thermal ellipsoids are shown at a 50% probability. The carbon atoms are shown in grey, nitrogen atoms in blue, the chlorine atoms in green, platinum in silver and gold in yellow. Selected bond distances (Å) and angles (°):  $d(\text{C}_{\text{Carbene}}-\text{Au}) = 1.964(10)$ ,  $d(\text{Au}-\text{Cl}) = 2.281(3)$ ,  $\angle(\text{N}, \text{C}_{\text{Carbene}}, \text{N}) = 116.3(9)$ ,  $\angle(\text{C}_{\text{Carbene}}, \text{Au}, \text{Cl}) = 176.3(3)$ ,  $d(\text{C}_{\text{Carbene}}-\text{Pd}) = 1.973(9)$ ,  $\angle(\text{N}, \text{C}_{\text{Carbene}}, \text{N}) = 114.8(8)$ ,  $d(\text{C}_{\text{Isonitrile}}-\text{Pd}) = 1.855(9)$ .

complexes **3a–k** with their gold(I) and palladium(II) containing counterparts **5a–j**, that were synthesized according to our previous work from amino functionalized carbene gold(I) complexes **2b–g** and the corresponding palladium isonitriles **4a–b** (Scheme 4).<sup>28</sup>

With the aim of exploring the potential anticancer effects of the heterobimetallic carbene gold(I) platinum(II) complexes object of this work, as well as the previously reported gold(I) palladium(II) congeners, we subjected a selection of human tumor cell lines (ovarian cancer A2780, high-grade serous ovarian cancer OVCAR-3, colon cancer HCT116, lung cancer A549 and triple-negative breast cancer MDA-MB231) to a 96 h treatment with both the synthesized compounds and cisplatin (utilized as a positive control). For the sake of completeness, we also tested some isonitrile platinum(II)- and palladium(II)- and amino functionalized carbene gold(I) complexes (**1b–c**, **4a–b** and **2b–g**, respectively). The stability of the newly synthesized heterobimetallic gold platinum complexes in the cell media was tested exemplarily with complex **3h** via <sup>1</sup>H NMR spectroscopy

(see ESI†). For this sake, the exemplary complex **3h** was dissolved in a mixture of a 100 mM saline solution in D<sub>2</sub>O and DMSO-*d*<sub>6</sub>. After 48 h at room temperature, **3h** did not depict any decomposition.

The results dealing with the antiproliferative activity of the tested compounds are reported in Table 1, presented as half inhibitory concentrations (IC<sub>50</sub>) values.

Although many of the tested compounds did not exhibit cytotoxicity towards most of the examined tumor cell lines, it is nonetheless possible to make interesting observations regarding the active compounds.


In the A2780 and OVCAR-3 ovarian cancer cell lines, among the tested amino functionalized carbene gold(I) complexes, **2c** emerged as the most active, displaying IC<sub>50</sub> values comparable to cisplatin in both cell lines. Conversely, complexes **2f** and **2g** were active only in the A2780 line. Among the heterobimetallic complexes, the majority of active compounds, albeit exhibiting moderate cytotoxicity, feature gold(I) and palladium(II) metal centers (**5d**, **5g**, and **5i**). Their IC<sub>50</sub> values generally ranged between 5 and 40 μM. Of particular interest is compound **5d**, which showed activity in both cell lines, albeit with lower cytotoxicity than cisplatin.

The promising antiproliferative activity of organopalladium complexes towards ovarian cancer cells is a recent and interesting topic in medicinal chemistry, since some derivatives reported in the literature have shown mechanisms of action markedly different from that of classical platinum-based anti-cancer agents.<sup>67,68</sup> Many derivatives have indeed demonstrated excellent activity against cisplatin-resistant ovarian cancer cell lines, as well as promising data in *ex vivo* (patient-derived organoids) and *in vivo* models.<sup>69–74</sup>

In the HCT116 line (colon cancer), a significant number (11) of compounds were active. The most active derivatives exhibited IC<sub>50</sub> values comparable to or even an order of magnitude lower than that obtained with cisplatin. Among these, noteworthy are the amino functionalized carbene gold(I) complexes **2b–c**, the isonitrile platinum(II) complexes **1b–c**, the heterobimetallic carbene gold(I) platinum(II) complex **3h**, and the heterobimetallic carbene gold(I) palladium(II) complexes **5b**, **5d**, and **5h**. Interestingly, the heterobimetallic carbene gold(I) platinum(II) complex **3h** and the heterobimetallic carbene gold(I) palladium(II) complex **5h**, both sharing a *para* substituted arene linker, exhibited remarkable cytotoxicity in the sub-micromolar range.

In the case of the MDA-MB-231 cells (triple-negative breast cancer), a substantial number of compounds were active against this aggressive subtype of breast cancer. All active compounds exhibited significantly higher cytotoxicity, up to two orders of magnitude, compared to cisplatin. Specifically, unlike the cell lines previously discussed, the most active compounds (IC<sub>50</sub> < 1 μM) contained at least one platinum(II) center (**1b**, **1c**, **3e**, and **3j**), with the exception of the heterobimetallic carbene gold(I) palladium(II) complex **5i**. Remarkably, the heterobimetallic complexes **3e**, **3j** and **5i**, sharing DIPP and Mes residues while differing in *meta*- and *para*-substituted arene linkers, showed low nanomolar IC<sub>50</sub> values.


#### a) Previously synthesized isonitrile palladium(II) complexes



**4a** R = DIPP

**4b** R = Mes

#### b) Previously synthesized heterobimetallic gold(I) palladium(II) complexes



Scheme 4 (a) Previously synthesized isonitrile palladium(II) complexes **4a–b**; (b) previously synthesized heterobimetallic gold(I) palladium(II) complexes **5a–j**; DIPP = 2,6-diisopropylphenyl-, Mes = mesityl-.



Table 1 Antiproliferative activity on A2780, OVCAR-3, HCT116, A549, MDA-MB-231 and MRC-5 cell lines<sup>a</sup>

Compound	IC <sub>50</sub> (μM)					
	A2780	OVCAR-3	HCT116	A549	MDA-MB-231	MRC-5
Cisplatin	0.6 ± 0.2	3.1 ± 0.2	7.9 ± 0.8	11 ± 1	15 ± 1	2 ± 1
<b>1b</b>	>100	>100	0.6 ± 0.5	>100	0.7 ± 0.5	>100
<b>1c</b>	>100	60 ± 30	1.0 ± 0.7	>100	0.24 ± 0.02	>100
<b>2b</b>	>100	>100	4.4 ± 0.2	>100	>100	>100
<b>2c</b>	2.8 ± 0.2	5 ± 1	4.4 ± 0.3	>100	3.9 ± 0.5	>100
<b>2d</b>	>100	>100	>100	>100	>100	>100
<b>2e</b>	>100	>100	>100	>100	>100	>100
<b>2f</b>	3.6 ± 0.2	>100	>100	>100	>100	>100
<b>2g</b>	1.9 ± 0.2	>100	>100	>100	>100	>100
<b>3a</b>	>100	>100	>100	>100	>100	>100
<b>3b</b>	>100	>100	>100	>100	>100	>100
<b>3c</b>	>100	>100	>100	>100	>100	>100
<b>3d</b>	>100	>100	>100	>100	>100	>100
<b>3e</b>	>100	>100	>100	>100	0.05 ± 0.04	>100
<b>3f</b>	>100	>100	>100	>100	>100	>100
<b>3g</b>	>100	>100	12 ± 7	>100	>100	>100
<b>3h</b>	>100	>100	0.5 ± 0.4	0.36 ± 0.01	>100	>100
<b>3i</b>	13.4 ± 0.2	>100	>100	>100	>100	>100
<b>3j</b>	>100	>100	>100	>100	0.2 ± 0.1	>100
<b>3k</b>	>100	>100	>100	>100	>100	>100
<b>3l</b>	>100	>100	14 ± 5	>100	>100	>100
<b>4a</b>	>100	>100	>100	>100	>100	>100
<b>4b</b>	>100	>100	>100	>100	24 ± 4	>100
<b>5a</b>	>100	40 ± 4	>100	>100	>100	>100
<b>5b</b>	>100	>100	5.2 ± 0.2	>100	>100	>100
<b>5c</b>	>100	20 ± 3	40 ± 20	12 ± 1	6 ± 1	>100
<b>5d</b>	12 ± 2	26 ± 2	7.2 ± 0.8	30 ± 4	6 ± 1	>100
<b>5e</b>	>100	80 ± 10	>100	>100	>100	>100
<b>5f</b>	>100	>100	33 ± 4	>100	>100	>100
<b>5g</b>	5 ± 1	>100	>100	>100	>100	>100
<b>5h</b>	>100	>100	0.3 ± 0.2	>100	>100	>100
<b>5i</b>	30 ± 10	>100	>100	>100	0.25 ± 0.02	6 ± 1
<b>5j</b>	>100	40 ± 10	>100	23 ± 4	17 ± 1	>100

<sup>a</sup> Data after 96 h of incubation. Stock solutions in DMSO for all complexes; stock solutions in H<sub>2</sub>O for cisplatin. A2780 (cisplatin-sensitive ovarian cancer cells), OVCAR-3 (high-grade serous ovarian cancer cells), HCT116 (colon cancer cells), MDA-MB-231 (triple-negative breast cancer cells), A549 (lung cancer cells), MRC-5 (non-cancerous lung fibroblasts).

In the A549 cell line (lung cancer), only four compounds among those tested were active (**3h**, **5c**, **5d**, and **5j**). Remarkably, the heterobimetallic carbene gold(i) platinum(ii) compound **3h** showed an IC<sub>50</sub> value one order of magnitude lower than that of cisplatin. All the other three complexes have gold(i) and palladium(ii) as central atoms, with IC<sub>50</sub> values comparable to that of cisplatin.

Overall, although compounds **5c** and **5d** are interesting as they are moderately active in at least four out of the five tested cell lines, we strongly believe that the most promising candidate warranting further investigation in future studies is the heterobimetallic carbene gold(i) platinum(ii) complex **3h**. This compound exhibits a specific and potent antiproliferative activity against colon and lung cancer cells, with IC<sub>50</sub> values markedly lower than those obtained with cisplatin.

Notably, complex **3h**, as well as most of the tested compounds, was inactive towards non-cancerous MRC-5 lung fibroblasts, thus suggesting an interesting *in vitro* selectivity towards cancer cells. In contrast, cisplatin did not exhibit *in*

*vitro* selectivity, as the IC<sub>50</sub> value determined on MRC-5 normal cells (2 ± 1 μM) is comparable to the IC<sub>50</sub> values obtained in the five tumor lines.

To the best of our knowledge, this is one of the few contributions systematically comparing the activity of platinum and palladium complexes bearing the same organometallic fragments.<sup>75,76</sup>

This comparison is often difficult to make as it is not always obvious to synthesize organopalladium complexes and their organoplatinum congeners while maintaining the same chemical environment.

More specifically, the synthetic protocol developed by our group allowed us to evaluate this effect by incorporating a carbene gold(i) moiety into the structure of the complexes under examination. Given the significant importance of gold in medicinal chemistry,<sup>77–79</sup> especially in cancer therapy, we firmly believe that the structures and data proposed in this work represent an added value in this fruitful research area.



Moreover, intrigued by the promising antiproliferative activity of the heterobimetallic carbene gold(i) platinum(ii) complex **3h** towards colon and lung cancer cells, we investigated both its potential interaction with DNA, which is typical of platinum-based anticancer agents, as well as the cellular uptake.

In particular, the structure of complex **3h** was fully optimized at ZORA-BLYP-D3(BJ)/TZ2P level of theory (see Computational details)<sup>80–83</sup> to generate a good structure as well as reliable partial atomic charges for the docking simulations. The binding poses and interactions between **3h** and DNA were studied by molecular docking simulations. Complex **3h** binds in the major groove region of the DNA (sequence d(CGCGAATTCGCG)<sub>2</sub>), where H-bonds and hydrophobic interactions with nucleotide residues (Fig. 2) are established, in a similar way as previously reported for Au and Pt complexes.<sup>84</sup> The binding of complex **3h** is thermodynamically favourable ( $\Delta G = -7.4$  kcal mol<sup>-1</sup>) indicating that the ligand–receptor complex is stable. The dA5 and dC23 residues are involved in H-bonds with complex **3h**, while the dG4 and dG22 interact by hydrophobic ( $\pi$ – $\pi$  stacking) interactions. The simulations also indicate that only the Pt atom of the complex interacts with the nucleotide bases (Pt...N interactions with dG4 and dA5), suggesting a possible covalent bond formation, in a similar way to cisplatin (Fig. S49†). Although tempting, it is not possible to compare directly the binding energies of **3h** and cisplatin (docking simulation is shown in the ESI†) because for small compounds the energy predictions is strongly influenced by their size.<sup>85</sup>

Finally, with the aim of explaining the higher cytotoxicity of complex **3h** compared to other heterobimetallic carbene gold(i) platinum(ii) complexes, we opted to study the cellular uptake of **3h** and **3e** (chosen as model compound) in A549 cancer cells. Specifically, we treated A549 cancer cells with a concentration of 1  $\mu$ M of each complex and monitored the cellular uptake of gold at three time points (3, 6, and 24 hours) using ICP-MS. The results are summarized in Table 2.

The cellular uptake data suggest that the superior cytotoxicity of complex **3h** may be linked, among several factors, to a faster uptake (*ca.* one order of magnitude difference after 3

Table 2 Cellular uptake of **3h** and **3e** on A549 cancer cells at different timepoints (ng of gold/2  $\times 10^6$  cells)

Au (ng/2 $\times 10^6$ cells)		
Time (h)	<b>3h</b>	<b>3e</b>
3	54.3 $\pm$ 0.8	5.9 $\pm$ 0.1
6	74.0 $\pm$ 0.4	10.44 $\pm$ 0.05
24	81 $\pm$ 1	78 $\pm$ 1

hours). However, since the uptake of the two compounds is very similar after 24 hours, we believe that the distinct structural characteristics of the two complexes also contribute to this marked difference in antiproliferative activity.

## Conclusions

Based on the isonitrile route to carbene complexes, we were able to synthesize a range of heterobimetallic carbene gold(i) platinum(ii) complexes in a straightforward and protecting group free approach. Also, a one pot protocol was employed, furnishing the desired complexes equally efficient compared to the corresponding multistep procedure. All complexes were characterized spectroscopically and were tested as potential anticancer agents against different cell lines and compared to their gold(i) palladium(ii) counterparts.

In particular, the most promising complex is the heterobimetallic carbene gold(i) platinum(ii) complex **3h**, which has demonstrated potent antiproliferative activity towards colon and lung cancer cells. Notably, this compound, as well as most of the active complexes, exhibited an interesting *in vitro* selectivity towards cancer cells over normal ones.

Moreover, the interaction between complex **3h** and DNA was studied *in silico*, demonstrating a thermodynamically favourable binding. Specifically, the interaction involves only the Pt atom of the complex with the nucleotide bases (dG4 and dA5), thus suggesting a possible covalent bond formation.

Further investigations concerning the synthesis of heterobimetallic complexes with other metal centers are ongoing in our laboratories.

## Data availability

The authors declare that all the data used for this manuscript can be found in its ESI.† The single crystal structure used in this manuscript has been assigned the CCDC number 2339445.

## Author contributions

Martin C. Dietl: conceptualization, investigation, methodology formal analysis and validation of analytical data, visualisation, writing-original draft; Melina Maag: investigation; Sophia Ber: investigation; Frank Rominger: data curation, formal analysis, validation and visualisation of X-ray Single Crystal Data; Matthias Rudolph: project administration, writing-review and editing; Isabella Caligiuri: investigation; Pacome Kossivi




Fig. 2 Molecular docking between DNA and metal complexes. (A) Binding pose of complex **3h** with DNA represented by surfaces. (B) Complex **3h** interaction with DNA. (C) Another view of the complex **3h** binding pose. DNA is shown by the strands and rings in red, blue, pink, and green indicating deoxyadenosine (dA), deoxythymidine (dT), deoxycytidine (dC), and deoxyguanosine (dG) residues, respectively. Hydrophobic, H-bonds, and Pt...N interactions are represented by purple, green, and red dashed lines with their respective distances in Å. The ligands are shown by a ball-and-stick model, with the Pt and Au atoms represented by steel blue and golden yellow colors, respectively.



Andele: investigation; Ibraheem A. I. Mkhalid: conceptualization; Flavio Rizzolio: investigation, methodology formal analysis and validation of analytical data; Pablo A. Nogara: data curation, formal analysis, validation and visualisation of molecular docking data, writing-review and editing; Laura Orian: data curation, formal analysis, validation and visualisation of DFT data, writing-review and editing; Thomas Scatolin: supervision, writing-original draft, data curation; A. Stephen K. Hashmi: supervision, project administration, resources.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University under grant (14-130-35-HiCi). The authors therefore, acknowledge technical and financial support of KAU.

## References

- B. G. Cooper, J. W. Napoline and C. M. Thomas, *Catal. Rev.: Sci. Eng.*, 2012, **54**, 1–40.
- N. Wheatley and P. Kalck, *Chem. Rev.*, 1999, **99**, 3379–3420.
- A. M. Chapman, S. R. Flynn and D. F. Wass, *Inorg. Chem.*, 2016, **55**, 1017–1021.
- S. Sculfort and P. Braunstein, *Chem. Soc. Rev.*, 2011, **40**, 2741–2760.
- S. Deolka, O. Rivada-Wheelaghan, S. L. Aristizábal, R. R. Fayzullin, S. Pal, K. Nozaki, E. Khaskin and J. R. Khusnutdinova, *Chem. Sci.*, 2020, **11**, 5494–5502.
- G. Dübek, F. Hanusch, D. Munz and S. Inoue, *Angew. Chem., Int. Ed.*, 2020, **132**, 5872–5878.
- H. Molaee, S. M. Nabavizadeh, M. Jamshidi, M. Vilsmeier, A. Pfitzner and M. Samandar Sangari, *Dalton Trans.*, 2017, **46**, 16077–16088.
- K. J. Cluff, N. Bhuvanesh and J. Blümel, *Chem.–Eur. J.*, 2015, **21**, 10138–10148.
- H. E. Wagner, S. Hohnstein, M. G. Schußmann, L. A. Steppe and F. Breher, *Dalton Trans.*, 2019, **48**, 15397–15407.
- W.-X. Gao, H.-N. Zhang and G.-X. Jin, *Coord. Chem. Rev.*, 2019, **386**, 69–84.
- M. L. Saha, X. Yan and P. J. Stang, *Acc. Chem. Res.*, 2016, **49**, 2527–2539.
- R. Clérac, H. Miyasaka, M. Yamashita and C. Coulon, *J. Am. Chem. Soc.*, 2002, **124**, 12837–12844.
- C. L. Cahill, D. T. de Lill and M. Frisch, *CrystEngComm*, 2007, **9**, 15–26.
- X. Feng, Y.-Q. Feng, L. Liu, L.-Y. Wang, H.-L. Song and S.-W. Ng, *Dalton Trans.*, 2013, **42**, 7741–7754.
- K. Kawakita, Y. Kakiuchi, E. P. Beaumier, I. A. Tonks, H. Tsurugi and K. Mashima, *Inorg. Chem.*, 2019, **58**, 15155–15165.
- S. Termühlen, L. F. B. Wilm, P. D. Dutschke, A. Hepp and F. E. Hahn, *Organometallics*, 2021, **40**, 1565–1570.
- P. D. Dutschke, S. Bente, C. G. Daniliuc, J. Kinan, A. Hepp and F. E. Hahn, *Dalton Trans.*, 2020, **49**, 14388–14392.
- J. A. Mata, F. E. Hahn and E. Peris, *Chem. Sci.*, 2014, **5**, 1723–1732.
- P. Buchwalter, J. Rosé and P. Braunstein, *Chem. Rev.*, 2015, **115**, 28–126.
- P. Shukla, S. Das, P. Bag and A. Dey, *Inorg. Chem. Front.*, 2023, **10**, 4322–4357.
- J.-L. Liu, J.-Y. Wu, Y.-C. Chen, V. Mereacre, A. K. Powell, L. Ungur, L. F. Chibotaru, X.-M. Chen and M.-L. Tong, *Angew. Chem., Int. Ed.*, 2014, **53**, 12966–12970.
- L. Ma, L. Li and G. Zhu, *Inorg. Chem. Front.*, 2022, **9**, 2424–2453.
- A. van Niekerk, P. Chellan and S. F. Mapolie, *Eur. J. Inorg. Chem.*, 2019, **2019**, 3432–3455.
- A. Jain, *Coord. Chem. Rev.*, 2019, **401**, 213067.
- M. Redrado, V. Fernández-Moreira and M. C. Gimeno, *ChemMedChem*, 2021, **16**, 932–941.
- Y.-A. Deng, S.-J. Tang, M.-F. Wang, X. Ren, X.-L. Li, L.-Z. Zeng, D.-N. Ren, M.-R. Wang, W.-L. Xiao, Z.-Y. Cai, D. Zhang, H. Zhang and F. Gao, *Inorg. Chem. Front.*, 2023, **10**, 4552–4561.
- G. M. D. M. Rúbio, T. T. Y. Tan, A. Prado-Roller, J. M. Chin and M. R. Reithofer, *Inorg. Chem.*, 2022, **61**, 7448–7458.
- M. C. Dietl, V. Vethacke, A. Keshavarzi, F. F. Mulks, F. Rominger, M. Rudolph, I. A. I. Mkhalid and A. S. K. Hashmi, *Organometallics*, 2022, **41**, 802–810.
- C. Hubbert, M. C. Dietl, D. Zahner, F. Rominger, M. Rudolph and A. S. K. Hashmi, *Organometallics*, 2023, **42**, 2762–2770.
- D. Riedel, T. Wurm, K. Graf, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Adv. Synth. Catal.*, 2015, **357**, 1515–1523.
- A. S. K. Hashmi, T. Hengst, C. Lothschütz and F. Rominger, *Adv. Synth. Catal.*, 2010, **352**, 1315–1337.
- T. Wurm, F. Mulks, C. R. N. Böhring, D. Riedel, P. Zargaran, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Organometallics*, 2016, **35**, 1070–1078.
- P. Zargaran, T. Wurm, D. Zahner, J. Schiessl, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Adv. Synth. Catal.*, 2018, **360**, 106–111.
- C. Lothschütz, T. Wurm, A. Zeiler, A. F. v. Falkenhausen, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Chem.–Asian J.*, 2016, **11**, 342–346.
- V. Vethacke, V. Claus, M. C. Dietl, D. Ehjeij, A. Meister, J. F. Huber, L. K. Paschai Darian, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Adv. Synth. Catal.*, 2022, **364**, 536–554.
- A. S. K. Hashmi, C. Lothschütz, C. Böhring, T. Hengst, C. Hubbert and F. Rominger, *Adv. Synth. Catal.*, 2010, **352**, 3001–3012.
- L. Tschugajeff, M. Skanawy-Grigorjewa and A. Posnjak, *Z. Anorg. Allg. Chem.*, 1925, **148**, 37–42.
- G. Rouschias and B. L. Shaw, *J. Chem. Soc. D*, 1970, 183.
- F. Bonati and G. Minghetti, *Synth. Inorg. Met.-Org. Chem.*, 1971, **1**, 299–302.
- F. Bonati and G. Minghetti, *J. Organomet. Chem.*, 1973, **59**, 403–410.



- 41 I. Ott, *Coord. Chem. Rev.*, 2009, **253**, 1670–1681.
- 42 M. Fanelli, M. Formica, V. Fusi, L. Giorgi, M. Micheloni and P. Paoli, *Coord. Chem. Rev.*, 2016, **310**, 41–79.
- 43 B. W. Harper, A. M. Krause-Heuer, M. P. Grant, M. Manohar, K. B. Garbutcheon-Singh and J. R. Aldrich-Wright, *Chem.–Eur. J.*, 2010, **16**, 7064–7077.
- 44 C. Cullinane, G. B. Deacon, P. R. Drago, A. P. Erven, P. C. Junk, J. Luu, G. Meyer, S. Schmitz, I. Ott and J. Schur, *Dalton Trans.*, 2018, **47**, 1918–1932.
- 45 M. A. Bernd, E. B. Bauer, J. Oberkofler, A. Bauer, R. M. Reich and F. E. Kühn, *Dalton Trans.*, 2020, **49**, 14106–14114.
- 46 E. J. Anthony, E. M. Bolitho, H. E. Bridgewater, O. W. L. Carter, J. M. Donnelly, C. Imberti, E. C. Lant, F. Lermite, R. J. Needham, M. Palau, P. J. Sadler, H. Shi, F.-X. Wang, W. Zhang and Z. Zhang, *Chem. Sci.*, 2020, **11**, 12888–12917.
- 47 G. Gasser, I. Ott and N. Metzler-Nolte, *J. Med. Chem.*, 2011, **54**, 3–25.
- 48 P. Zhang and P. J. Sadler, *J. Organomet. Chem.*, 2017, **839**, 5–14.
- 49 E. Bortolamiol, F. Visentin and T. Scattolin, *Appl. Sci.*, 2023, **13**, 5561.
- 50 J. E. López-Hernández, N. Nayeem, J. P. Cerón-Carrasco, A. Lahad, A. Hafeed, I. E. León and M. Contel, *Chem.–Eur. J.*, 2023, **29**, e202302045.
- 51 N. Curado, N. Giménez, K. Miachin, M. Aliaga-Lavrijsen, M. Cornejo, A. A. Jarzęcki and M. Contel, *ChemMedChem*, 2019, **14**, 1086–1095.
- 52 R. A. Khan, A. Asim, R. Kakkar, D. Gupta, V. Bagchi, F. Arjmand and S. Tabassum, *Organometallics*, 2013, **32**, 2546–2551.
- 53 A. Herman, J. M. Tanski, M. F. Tibbetts and C. M. Anderson, *Inorg. Chem.*, 2007, **47**, 274–280.
- 54 J. E. López-Hernández and M. Contel, *Curr. Opin. Chem. Biol.*, 2023, **72**, 102250.
- 55 B. Bertrand, A. Citta, I. L. Franken, M. Picquet, A. Folda, V. Scalcon, M. P. Rigobello, P. L. Gendre, A. Casini and E. Bodio, *JBIC, J. Biol. Inorg. Chem.*, 2015, **20**, 1005–1020.
- 56 J. Banfić, A. A. Legin, M. A. Jakupec, M. Galanski and B. K. Keppler, *Eur. J. Inorg. Chem.*, 2014, 484–492.
- 57 K. Mitra, U. Basu, I. Khan, B. Maity, P. Kondaiah and A. R. Chakravarty, *Dalton Trans.*, 2014, **43**, 751–763.
- 58 C. M. Anderson, S. S. Jain, L. Silber, K. Chen, S. Guha, W. Zhang, E. C. McLaughlin, Y. Hu and J. M. Tanski, *J. Inorg. Biochem.*, 2015, **145**, 41–50.
- 59 C. Mu, S. W. Chang, K. E. Prosser, A. W. Y. Leung, S. Santacruz, T. Jang, J. R. Thompson, D. T. T. Yapp, J. J. Warren, M. B. Bally, T. V. Beischlag and C. J. Walsby, *Inorg. Chem.*, 2016, **55**, 177–190.
- 60 D. Aucamp, S. V. Kumar, D. C. Liles, M. A. Fernandes, L. Harmse and D. I. Bezuidenhout, *Dalton Trans.*, 2018, **47**, 16072–16081.
- 61 T. A. C. A. Bayrakdar, T. Scattolin, X. Ma and S. P. Nolan, *Chem. Soc. Rev.*, 2020, **49**, 7044–7100.
- 62 W. D. J. Tremlett, T. Söhnel, J. D. Crowley, L. J. Wright and C. G. Hartinger, *Inorg. Chem.*, 2023, **62**, 3616–3628.
- 63 A. S. Braegelman and M. J. Webber, *Theranostics*, 2019, **9**, 3017–3040.
- 64 A. Van Niekerk, P. Chellan and S. F. Mapolie, *Eur. J. Inorg. Chem.*, 2019, **2019**, 3432–3455.
- 65 A. P. M. Guedes, F. Mello-Andrade, W. C. Pires, M. A. M. De Sousa, P. F. F. Da Silva, M. Camargo, H. Gemeiner, M. A. Amauri, C. G. Cardoso, P. R. De Melo Reis, E. De Paula Silveira-Lacerda and A. A. Batista, *Metallomics*, 2020, **12**, 547–561.
- 66 T. B. Peters, J. C. Bohling, A. M. Arif and J. A. Gladysz, *Organometallics*, 1999, **18**, 3261–3263.
- 67 T. Scattolin, V. A. Voloshkin, F. Visentin and S. P. Nolan, *Cell Rep. Phys. Sci.*, 2021, **2**, 100446.
- 68 A. R. Kapdi and I. J. S. Fairlamb, *Chem. Soc. Rev.*, 2014, **43**, 4751–4777.
- 69 T. Scattolin, I. Pessotto, E. Cavarzerani, V. Canzonieri, L. Orian, N. Demitri, C. Schmidt, A. Casini, E. Bortolamiol, F. Visentin, F. Rizzolio and S. P. Nolan, *Eur. J. Inorg. Chem.*, 2022, e202200103.
- 70 T. Scattolin, E. Bortolamiol, F. Visentin, S. Palazzolo, I. Caligiuri, T. Perin, V. Canzonieri, N. Demitri, F. Rizzolio and A. Togni, *Chem.–Eur. J.*, 2020, **26**, 11868–11876.
- 71 T. Scattolin, E. Bortolamiol, S. Palazzolo, I. Caligiuri, T. Perin, V. Canzonieri, N. Demitri, F. Rizzolio, L. Cavallo, B. Dereli, M. V. Mane, S. P. Nolan and F. Visentin, *Chem. Commun.*, 2020, **56**, 12238–12241.
- 72 T. T.-H. Fong, C.-N. Lok, C. Y.-S. Chung, Y.-M. E. Fung, P.-K. Chow, P.-K. Wan and C.-M. Che, *Angew. Chem., Int. Ed.*, 2016, **55**, 11935–11939.
- 73 T. Scattolin, G. Tonon, E. Botter, S. G. Guillet, N. V. Tzouras and S. P. Nolan, *Chem.–Eur. J.*, 2023, **29**, e202301961.
- 74 T. Scattolin, A. A. Logvinov, N. V. Tzouras, C. S. J. Cazin and S. P. Nolan, *Organometallics*, 2023, **42**, 2692–2730.
- 75 T. Scattolin, G. Valente, L. Luziotti, M. Piva, N. Demitri, I. Lampronti, R. Gambari and F. Visentin, *Appl. Organomet. Chem.*, 2021, **35**, e6438.
- 76 J. E. López-Hernández and M. Contel, *Curr. Opin. Chem. Biol.*, 2023, **72**, 102250.
- 77 G. Moreno-Alcántar, P. Picchetti and A. Casini, *Angew. Chem., Int. Ed.*, 2023, **62**, e202218000.
- 78 P. J. Sadler and R. van Eldik, *Advances in Inorganic Chemistry: Medicinal Chemistry*, Academic Press, 2020.
- 79 R. P. Herrera and M. C. Gimeno, *Chem. Rev.*, 2021, **121**, 8311–8363.
- 80 A. Madabeni, P. A. Nogara, M. Bortoli, J. B. T. Rocha and L. Orian, *Inorg. Chem.*, 2021, **60**, 4646–4656.
- 81 M. Monticelli, M. Baron, C. Tubaro, S. Bellemin-Laponnaz, C. Graiff, G. Bottaro, L. Armelao and L. Orian, *ACS Omega*, 2019, **4**, 4192–4205.
- 82 P. A. Nogara, A. Madabeni, M. Bortoli, J. B. T. Rocha and L. Orian, *Chem. Res. Toxicol.*, 2021, **34**, 1655–1663.
- 83 A. Madabeni, T. Scattolin, E. Bortolamiol, F. Visentin and L. Orian, *Organometallics*, 2024, **43**, 954–962.
- 84 M. Sankarganesh, J. Dhavethu Raja, K. Sakthikumar, R. V. Solomon, J. Rajesh, S. Athimoolam and V. Vijayakumar, *Bioorg. Chem.*, 2018, **81**, 144–156.
- 85 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.

